Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

April 14, 2026 02:00 ET | Source: PannTheraPi

PannTheraPi annonce des avancées majeures dans son développement clinique et stratégique

PannTheraPi annonce des avancées majeures dans son développement clinique et stratégique Le dépôt du dossier réglementaire pour l’initiation de l’essai clinique de Phase 2a évaluant son candidat...
April 14, 2026 02:00 ET | Source: PannTheraPi

PannTheraPi Announces Significant Clinical Development and Strategic Milestones

PannTheraPi files Phase 2a trial for epilepsy drug PTI5803, secures EU patent, and appoints Sophie Binay as GM & CSO.
April 13, 2026 08:00 ET | Source: Lixte Biotechnology Holdings, Inc.

Favorable Results of Ovarian Cancer Study Presented at Annual Society of Gynecological Care Conference

-Trial Combines LIXTE’s LB-100 with Dostarlimab; Results Give Patients New Hope for a Challenging Disease with Limited Therapeutic Options- BOCA RATON, Fla., April 13, 2026 (GLOBE NEWSWIRE) --...
April 09, 2026 10:30 ET | Source: Cures Within Reach

Cures Within Reach Approves Five Clinical Trials at Chicago-based Research Institutions

Clinical trials are led by early-stage investigators and/or impact health equity, veterans and pediatricsFuture funding increased to offset cuts in medical research funding CHICAGO, April 09, 2026 ...
March 31, 2026 08:00 ET | Source: Adcytherix

Adcytherix Doses First Patient in Phase 1 Trial of ADCX-020 and Strengthens Leadership to Support Next Phase of Growth

Dosing of the first patient in the Phase 1 clinical trial of ADCX-020.
March 24, 2026 08:00 ET | Source: Calidi Biotherapeutics, Inc

Calidi Biotherapeutics Announces Partnership with Avance Clinical to Facilitate Australian Regulatory Approval and Accelerate Initiation of CLD-401 Clinical Trials

SAN DIEGO, March 24, 2026 (GLOBE NEWSWIRE) -- Calidi Biotherapeutics, Inc. (NYSE American: CLDI) (“Calidi” or the “Company”), a biotechnology company pioneering the development of targeted genetic...
March 24, 2026 06:00 ET | Source: Yatiri Bio

Yatiri Bio Enters Exclusive Option to In-License Agreement with Oscotec for Denfivontinib in AML

Yatiri Bio is a precision medicine company focused on identifying and validating biomarkers that predict therapeutic response in oncology.
March 23, 2026 08:30 ET | Source: Biodexa Pharmaceuticals PLC

Biodexa Launches Global Early Access Program for eRapa for FAP Patients Through Strategic Partnership with Tanner Pharma Group

March 23, 2026 Biodexa Launches Global Early Access Program for eRapa for FAP Patients Through Strategic Partnership with Tanner Pharma Group Biodexa Pharmaceuticals PLC (Nasdaq: BDRX), a clinical...
March 19, 2026 12:40 ET | Source: Royal Columbian Hospital Foundation

New partnership to fast-track Canadian health technology from innovation to patient care

AIM Institute and CAN Health Network join forces to help Canadian solutions reach clinicians and patients faster NEW WESTMINSTER, British Columbia, March 19, 2026 (GLOBE NEWSWIRE) -- Royal...
March 16, 2026 09:00 ET | Source: Vigo Consulting Limited

Elevara Medicines Doses First Patient in Phase 2b START-SYNERGY Trial of ELV001 in Rheumatoid Arthritis Patients with Incomplete Response to TNFi

Elevara Medicines announces dosing of the first patient in its Phase 2b START-SYNERGY clinical trial evaluating ELV001, a novel oral CDK4/6 inhibitor.